On the other hand, we see an increase in risk-weighted assets up to the crisis, with a slight drop afterwards and the trend steadying since then. The deal will free up capital of some EUR 400 million, primarily by reducing risk-weighted assets by EUR 4.
The Heska Corporation is involved in biotechnical research for the development of vaccines and related diagnostic products for companion animals. The company manufactures health care products for dogs, cats, and horses and markets them to veterinarians.
Heska Imaging reported unaudited revenue results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue of $2.1 million compared to $1.9 million in the prior year period.